Psoriasis

Johnson & Johnson’s JNJ-2113 showed promise for PsO, achieving high skin clearance with a strong safety profile.

Stark highlighted Bimzelx’s role in treating psoriasis and HS, introduced the BE BOLD study for PsA, and looked to future innovation in inflammatory skin disease.

According to a poster from AAD, the National Psoriasis Foundation’s treatment goals were used as a benchmark to determine the risk of developing psoriatic arthritis after initiating biologics.

Findings suggest that most patients on risankizumab met or exceeded the National Psoriasis Foundation’s treatment goals.

At AAD 2025, Raj Chovatiya, MD, PhD, MSCI, explored the role of social determinants in AD, HS, and PsO, emphasizing the need for improved clinical recognition and inclusive research.

At AAD 2025, UCB will present 5-year data for Bimzelx in psoriasis, highlighting rapid, durable responses and long-term safety for patients.

Patrick Burnett, MD, PhD, shares key updates expected in 2025 for therapeutics treating atopic dermatitis, alopecia areata, and more.

Robinson shared insights into how the company is working to fight clinical research disparities.

Psoriasis trials are among the least diverse within dermatology, with participants predominantly being white men.

Belgian patients receiving biologics had faster response rates compared to phototherapy, systemic, and topical treatments.

Ustekinumab-kfce is available for the treatment of chronic autoimmune conditions like Crohn’s disease, ulcerative colitis, and plaque psoriasis.

This study highlights the urgent need for improved awareness, diagnosis, and treatment of inflammatory nail diseases in patients with skin of color.

The POETYK PSO LTE trial found deucravacitinib effective in sustaining PASI 75 and PASI 90 responses.

VYNE has initiated a phase 1b trial for its oral BD2-selective BET inhibitor.

Hispanic and non-White patients with psoriatic arthritis (PsA) had higher tender joint counts and greater disease severity, highlighting racial and ethnic disparities in PsA disease burden and treatment outcomes.

Advances in biologics, JAK inhibitors, and PDE4 inhibitors provide personalized options for psoriasis management.

A holistic yet time-efficient approach can help dermatologists recognize early joint pain symptoms associated with psoriasis.

New data reveals an unmet need in the management of moderate to severe psoriasis in Greek patients.

The new dose offers a more tailored and convenient option for patients with inflammatory conditions.

Following his presentation at Winter Clinical Miami, Del Rosso spoke to Dermatology Times about the current treatment landscape of psoriasis.

The IL-36R antagonist has demonstrated its safety and efficacy for generalized pustular psoriasis in GEMINI-1 and GEMINI-2 studies.

At the Horizons in Advanced Practice meeting, Douglas DiRuggiero, DMSc, MHS, PA-C, presented a case of a man aged 47 years with a history of moderate psoriasis for 3 years and a recent diagnosis of psoriatic arthritis

At the Horizons in Advanced Practice meeting, Omar Noor, MD, FAAD, presented a case of a man aged 70 years with a 20-year history of psoriasis who was previously treated with adalimumab.

These efficacy results and safety profile confirm what was observed in phase 1 study.